Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Recurrence 1 Paraproteinemias 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Multiple Myeloma 1 Lymphoproliferative Disorders 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Immunoproliferative Disorders 1 Hematologic Diseases 1 Glioma 1 Blood Protein Disorders 1

Interventions

Temozolomide 69 Bevacizumab 40 Radiotherapy 22 Magnetic Resonance Spectroscopy 20 Irinotecan 17 Specimen Handling 10 Carboplatin 10 Carmustine 9 X-Rays 7 Radiation 7 olaparib 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Nuclear Medicine Department, Hospital 6 Nivolumab 6 Everolimus 6 Cyclophosphamide 6 Biopsy 6 trametinib 5 Thalidomide 5 Cisplatin 5 pembrolizumab 4 palbociclib 4 fluorodopa F 18 4 erdafitinib 4 dabrafenib 4 Lomustine 4 Etoposide 4 Drug Therapy 4 Doxorubicin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × CLR1404 × Clear all

NCT01778088 2014-02-25

Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

Cellectar Biosciences, Inc.

Phase 2 Withdrawn

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡